Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine XR vs SSRIs/Conventional Antidepressants in MDD Switchers
NCT00474708Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of venlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Pfizer. Primary endpoint: Number of Patients Achieving Remission at 12 weeks. Started Apr 2007; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00474708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474708.